Clinic Diagnostic Nuclear Medicine Radiation Oncology 
AuntMinnie
JULY 12, 2024
As nuclear medicine therapies gain stature compared to nuclear medicine in diagnostic imaging, hospital administrators may be eyeing the potential of adding theranostics services. A shortage of nuclear medicine technologists means a theranostics center may need to limit its patient volume.
Imaging Technology
JULY 3, 2023
professor of the Department of Radiation Oncology and the Department of Immunology and Theranostics at City of Hope , and principal investigator of the RefleXion-supported PyL imaging study. professor and chair of City of Hope’s Department of Radiation Oncology. “As
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Imaging Technology
SEPTEMBER 14, 2023
milla1cf Thu, 09/14/2023 - 15:17 September 14, 2023 — Mayo Clinic and GE HealthCare announce a strategic healthcare collaboration for research and product development programs aimed to transform the experience of patients and clinicians in the practice of radiology and the delivery of novel therapies.
AuntMinnie
APRIL 4, 2024
Even if some private urology, radiation oncology practices, or radiologist groups are building the ability to perform theranostics, experts are cautious about patient management, radiation safety, and the risk of unnecessary imaging. Theranostics is becoming a treatment option for a larger volume of cancer patients. Hope added.
AuntMinnie
MARCH 26, 2024
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. After binding to the receptor, the drug works by entering the cell allowing radiation to cause damage to the tumor cells.
Imaging Technology
JANUARY 8, 2024
Recognizing the industry transformation taking place as digital innovation reshapes the experience of patients and providers, GE HealthCare – a leading global medical technology, pharmaceutical diagnostics, and digital innovator – is focused on developing smart devices, aligned to disease states and enabled by digital.
AuntMinnie
JANUARY 26, 2024
In a comparative imaging trial, fibroblast activation protein inhibitor (FAPI)-PET/CT outperformed FDG-PET/CT in detecting primary tumors in patients with head and neck cancer, according to a study published January 25 in the Journal of Nuclear Medicine. Image courtesy of the Journal of Nuclear Medicine.
Expert insights. Personalized for you.
105 
Let's personalize your content